Updated Screening Guidelines for 5 Cancer Types
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic. -
Blood-Based Test May Establish a ‘New Paradigm’ for Cancer Screening
The test can accurately detect cancer and predict where it is located, according to researchers. -
Overcoming Obstacles to Health Equity in Breast Cancer Prevention and Control
The current scientific evidence may not be generalizable to underrepresented groups. -
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
Artificial Intelligence Not Yet Ready for Clinical Breast Cancer Screening
Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
Novel Antibody-Drug Conjugate May Improve PFS in Advanced Breast Cancer
Trastuzumab Deruxtecan: A New Standard for Second-Line Therapy in HER2+ Metastatic Breast Cancer?
Adding Carboplatin to Neoadjuvant Chemo Improves EFS in Triple-Negative Breast Cancer
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer
Loading... 
Loading...